Q3 2024 Mediwound Ltd Earnings Call Transcript
Key Points
- MediWound Ltd (MDWD) received FDA approval for NexoBrid's pediatric use in the United States, expanding its label to cover patients from newborn to 18 years old.
- NexoBrid's commercial revenue met expectations, with significant progress in the U.S. market, including submissions to over 70 burn centers.
- The World Health Organization designated enzymatic debridement as an essential treatment for burn injuries, reinforcing NexoBrid's role in emergency response.
- MediWound completed construction of a new GMP-compliant manufacturing facility, expected to increase manufacturing output sixfold by the end of 2025.
- The company secured $25 million through a private investment led by Molnlycke Healthcare, enhancing its strategic funding and commercial expertise.
- Revenue for the third quarter of 2024 decreased to $4.4 million from $4.8 million in the same period of 2023, primarily due to lower revenue from BARDA Development Services.
- Gross profit for the quarter declined to $0.7 million, representing 16% of total revenue, compared to $0.9 million or 90% of total revenue in Q3 2023.
- Operating loss for the first nine months of 2024 was $13.3 million, compared to $11.4 million in the same period of 2023.
- Net loss for the first nine months increased significantly to $26.3 million or $2.72 per share, compared to a net loss of $5 million or $0.56 per share in the same period of 2023.
- The anticipated revenue for 2024 was adjusted down to $20 million from prior guidance of $24 million, due to capacity constraints and reduced BARDA funding.
Good day, and welcome to the MediWound third-quarter 2024 earnings call. (Operator instructions) Please note this event is being recorded.
I would now like to turn the conference over to Mr. Dan Ferry of Life Advisors. Please go ahead, sir.
Thank you, operator, and welcome, everyone. Today, before the market opened, MediWound issued a press release announcing financial results for the third quarter ended September 30, 2024. You may access that release on the company's website under the Investors tab.
With us today are Ofer Gonen, Chief Executive Officer of MediWound; Hani Luxenburg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development.
Following our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to MediWound's expected future performance, future business prospects or future events or plans are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
